FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1860-1873 October 28, 2004 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

Multiple myeloma is a plasma-cell neoplasm that is characterized by skeletal destruction, renal failure, anemia, and hypercalcemia.¹ Although myeloma remains incurable, recent advances in its treatment, including the use of thalidomide and new drugs such as bortezomib and CC-5013, are promising.²

Diagnosis

The most common symptoms on presentation are fatigue, bone pain, and recurrent infections.³ New diagnostic criteria require the presence of at least 10 percent plasma cells on examination of the bone marrow (or biopsy of a tissue with monoclonal plasma cells), monoclonal protein in the serum or urine, and evidence of end-organ damage.^4,5 The end-organ damage that meets the . . . [Full Text of this Article]

Pathophysiology

Evolution of MGUS

Progression to Myeloma

Therapy

Induction Therapy in Patients Eligible for Autologous Stem-Cell Transplantation

Induction Therapy in Patients Not Eligible for Transplantation

Autologous Stem-Cell Transplantation

Tandem Transplantation

Allogeneic Transplantation

Maintenance Therapy

Therapy for Relapsed and Refractory Multiple Myeloma

Thalidomide

Clinical Trials

Adverse Effects

Dosage

Mechanism of Action

Bortezomib

Clinical Trials

Adverse Effects

Dosing

Mechanism of Action

CC-5013

Other Novel Agents

Treatment of Complications

Future Directions

Source Information

From the Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota.

Address reprint requests to Dr. Kyle at the Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St. S.W., Rochester, MN 55905, or at kyle.robert@mayo.edu.

Related Letters:

Multiple Myeloma
Altundag K., Altundag O., Gundeslioglu O., Crawford C. L., Schneider H. G., Sentry J., Kyle R. A., Rajkumar S. V.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:840-841, Feb 24, 2005. Correspondence

This article has been cited by other articles:

• Audard, V., Georges, B., Vanhille, P., Toly, C., Deroure, B., Fakhouri, F., Cuvelier, R., Belenfant, X., Surin, B., Aucouturier, P., Mougenot, B., Ronco, P. (2008). Renal Lesions Associated with IgM-Secreting Monoclonal Proliferations: Revisiting the Disease Spectrum. CJASN 3: 1339-1349 [Abstract] [Full Text]  
• San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., Dmoszynska, A., Abdulkadyrov, K. M., Schots, R., Jiang, B., Mateos, M.-V., Anderson, K. C., Esseltine, D. L., Liu, K., Cakana, A., van de Velde, H., Richardson, P. G., the VISTA Trial Investigators, (2008). Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. NEJM 359: 906-917 [Abstract] [Full Text]  
• Giuliani, N., Lisignoli, G., Colla, S., Lazzaretti, M., Storti, P., Mancini, C., Bonomini, S., Manferdini, C., Codeluppi, K., Facchini, A., Rizzoli, V. (2008). CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3{alpha} and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions. Cancer Res. 68: 6840-6850 [Abstract] [Full Text]  
• Marathe, A., Peterson, M. C., Mager, D. E. (2008). Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients. J. Pharmacol. Exp. Ther. 326: 555-562 [Abstract] [Full Text]  
• Airoldi, I., Cocco, C., Giuliani, N., Ferrarini, M., Colla, S., Ognio, E., Taverniti, G., Di Carlo, E., Cutrona, G., Perfetti, V., Rizzoli, V., Ribatti, D., Pistoia, V. (2008). Constitutive expression of IL-12R{beta}2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 112: 750-759 [Abstract] [Full Text]  
• Yeung, J, Chang, H (2008). Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J. Clin. Pathol. 61: 832-836 [Abstract] [Full Text]  
• Huff, C. A., Matsui, W. (2008). Multiple Myeloma Cancer Stem Cells. JCO 26: 2895-2900 [Abstract] [Full Text]  
• Lorenz, E. C., Gertz, M. A., Fervenza, F. C., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Gastineau, D. A., Leung, N. (2008). Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 23: 2052-2057 [Abstract] [Full Text]  
• Rajkumar, S. V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., Blade, J. (2008). Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. JCO 26: 2171-2177 [Abstract] [Full Text]  
• Chatterjee, M., Rancso, C., Stuhmer, T., Eckstein, N., Andrulis, M., Gerecke, C., Lorentz, H., Royer, H.-D., Bargou, R. C. (2008). The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 111: 3714-3722 [Abstract] [Full Text]  
• Brown, L. M., Gridley, G., Check, D., Landgren, O. (2008). Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111: 3388-3394 [Abstract] [Full Text]  
• Kyle, R. A., Rajkumar, S. V. (2008). Multiple myeloma. Blood 111: 2962-2972 [Abstract] [Full Text]  
• Ghobrial, I. M., Anderson, K. C. (2008). The road to cure in multiple myeloma. Blood 111: 2503-2503 [Full Text]  
• Perez, L. E., Parquet, N., Shain, K., Nimmanapalli, R., Alsina, M., Anasetti, C., Dalton, W. (2008). Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP. J. Immunol. 180: 1545-1555 [Abstract] [Full Text]  
• Niesvizky, R., Jayabalan, D. S., Christos, P. J., Furst, J. R., Naib, T., Ely, S., Jalbrzikowski, J., Pearse, R. N., Zafar, F., Pekle, K., LaRow, A., Lent, R., Mark, T., Cho, H. J., Shore, T., Tepler, J., Harpel, J., Schuster, M. W., Mathew, S., Leonard, J. P., Mazumdar, M., Chen-Kiang, S., Coleman, M. (2008). BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood 111: 1101-1109 [Abstract] [Full Text]  
• Bensinger, W. (2008). Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs. JCO 26: 480-492 [Abstract] [Full Text]  
• Matsui, W., Wang, Q., Barber, J. P., Brennan, S., Smith, B. D., Borrello, I., McNiece, I., Lin, L., Ambinder, R. F., Peacock, C., Watkins, D. N., Huff, C. A., Jones, R. J. (2008). Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. Cancer Res. 68: 190-197 [Abstract] [Full Text]  
• Wang, L. H., Yang, X. Y., Zhang, X., Farrar, W. L. (2007). Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPAR{gamma} cross talk with NF-{kappa}B and C/EBP. Blood 110: 4373-4384 [Abstract] [Full Text]  
• Dingli, D., Pacheco, J. M., Nowakowski, G. S., Kumar, S. K., Dispenzieri, A., Hayman, S. R., Lacy, M. Q., Gastineau, D. A., Gertz, M. A. (2007). Relationship Between Depth of Response and Outcome in Multiple Myeloma. JCO 25: 4933-4937 [Abstract] [Full Text]  
• Dimopoulos, M. A., Souliotis, V. L., Anagnostopoulos, A., Bamia, C., Pouli, A., Baltadakis, I., Terpos, E., Kyrtopoulos, S. A., Sfikakis, P. P. (2007). Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. haematol 92: 1505-1512 [Abstract] [Full Text]  
• Rajkumar, S. V., Richardson, P. G., Lacy, M. Q., Dispenzieri, A., Greipp, P. R., Witzig, T. E., Schlossman, R., Sidor, C. F., Anderson, K. C., Gertz, M. A. (2007). Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma. Clin. Cancer Res. 13: 6162-6167 [Abstract] [Full Text]  
• Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omede, P., Ambrosini, M. T., Gay, F., Bringhen, S., Musto, P., Foa, R., Knight, R., Zeldis, J. B., Boccadoro, M., Petrucci, M. T. (2007). Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network. JCO 25: 4459-4465 [Abstract] [Full Text]  
• Murphy, P. T., O'Donnell, J. R. (2007). Thalidomide induced impotence in male hematology patients: a common but ignored complication?. haematol 92: 1440-1440 [Abstract] [Full Text]  
• Neri, P., Kumar, S., Fulciniti, M. T., Vallet, S., Chhetri, S., Mukherjee, S., Tai, Y., Chauhan, D., Tassone, P., Venuta, S., Munshi, N. C., Hideshima, T., Anderson, K. C., Raje, N. (2007). Neutralizing B-Cell Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model. Clin. Cancer Res. 13: 5903-5909 [Abstract] [Full Text]  
• Orlowski, R. Z., Nagler, A., Sonneveld, P., Blade, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., Spicka, I., Sutherland, H. J., Suvorov, A. N., Zhuang, S. H., Parekh, T., Xiu, L., Yuan, Z., Rackoff, W., Harousseau, J.-L. (2007). Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. JCO 25: 3892-3901 [Abstract] [Full Text]  
• Giuliani, N., Morandi, F., Tagliaferri, S., Lazzaretti, M., Donofrio, G., Bonomini, S., Sala, R., Mangoni, M., Rizzoli, V. (2007). Production of Wnt Inhibitors by Myeloma Cells: Potential Effects on Canonical Wnt Pathway in the Bone Microenvironment. Cancer Res. 67: 7665-7674 [Abstract] [Full Text]  
• van Rhee, F., Bolejack, V., Hollmig, K., Pineda-Roman, M., Anaissie, E., Epstein, J., Shaughnessy, J. D. Jr, Zangari, M., Tricot, G., Mohiuddin, A., Alsayed, Y., Woods, G., Crowley, J., Barlogie, B. (2007). High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 110: 827-832 [Abstract] [Full Text]  
• Younes, H., Leleu, X., Hatjiharissi, E., Moreau, A.-S., Hideshima, T., Richardson, P., Anderson, K. C., Ghobrial, I. M. (2007). Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma. Clin. Cancer Res. 13: 3771-3775 [Abstract] [Full Text]  
• Trudel, S., Li, Z. H., Rauw, J., Tiedemann, R. E., Wen, X. Y., Stewart, A. K. (2007). Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109: 5430-5438 [Abstract] [Full Text]  
• Landgren, O., Turesson, I., Gridley, G., Caporaso, N. E. (2007). Risk of Malignant Disease Among 1525 Adult Male US Veterans With Gaucher Disease. Arch Intern Med 167: 1189-1194 [Abstract] [Full Text]  
• Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S., Baccarani, M. (2007). Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. JCO 25: 2434-2441 [Abstract] [Full Text]  
• Largo, C., Saez, B., Alvarez, S., Suela, J., Ferreira, B., Blesa, D., Prosper, F., Calasanz, M. J., Cigudosa, J. C. (2007). Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations. haematol 92: 795-802 [Abstract] [Full Text]  
• Oyajobi, B. O., Munoz, S., Kakonen, R., Williams, P. J., Gupta, A., Wideman, C. L., Story, B., Grubbs, B., Armstrong, A., Dougall, W. C., Garrett, I. R., Mundy, G. R. (2007). Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Molecular Cancer Therapeutics 6: 1701-1708 [Abstract] [Full Text]  
• Kristinsson, S. Y., Landgren, O., Dickman, P. W., Derolf, A. R., Bjorkholm, M. (2007). Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. JCO 25: 1993-1999 [Abstract] [Full Text]  
• Colla, S., Zhan, F., Xiong, W., Wu, X., Xu, H., Stephens, O., Yaccoby, S., Epstein, J., Barlogie, B., Shaughnessy, J. D. Jr (2007). The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 109: 4470-4477 [Abstract] [Full Text]  
• Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W. J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., Trepicchio, W. L., Broyl, A., Sonneveld, P., Shaughnessy, J. D. Jr, Leif Bergsagel, P., Schenkein, D., Esseltine, D.-L., Boral, A., Anderson, K. C. (2007). Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109: 3177-3188 [Abstract] [Full Text]  
• Carlo-Stella, C., Guidetti, A., Di Nicola, M., Lavazza, C., Cleris, L., Sia, D., Longoni, P., Milanesi, M., Magni, M., Nagy, Z., Corradini, P., Carbone, A., Formelli, F., Gianni, A. M. (2007). IFN-{gamma} Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. Cancer Res. 67: 3269-3275 [Abstract] [Full Text]  
• Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U. K., Pitsillides, C. M., Spencer, J. A., Kimlinger, T., Ghobrial, J. M., Jia, X., Lu, G., Timm, M., Kumar, A., Cote, D., Veilleux, I., Hedin, K. E., Roodman, G. D., Witzig, T. E., Kung, A. L., Hideshima, T., Anderson, K. C., Lin, C. P., Ghobrial, I. M. (2007). Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109: 2708-2717 [Abstract] [Full Text]  
• Palumbo, A., Ambrosini, M. T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., Bringhen, S., Falco, P., Avonto, I., Cavallo, F., Boccadoro, M., for the Italian Multiple Myeloma Network, Gruppo I, (2007). Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109: 2767-2772 [Abstract] [Full Text]  
• Walker, R., Barlogie, B., Haessler, J., Tricot, G., Anaissie, E., Shaughnessy, J. D. Jr, Epstein, J., van Hemert, R., Erdem, E., Hoering, A., Crowley, J., Ferris, E., Hollmig, K., van Rhee, F., Zangari, M., Pineda-Roman, M., Mohiuddin, A., Yaccoby, S., Sawyer, J., Angtuaco, E. J. (2007). Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications. JCO 25: 1121-1128 [Abstract] [Full Text]  
• Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omede, P., Baldi, I., Bringhen, S., Massaia, M., Aglietta, M., Levis, A., Gallamini, A., Fanin, R., Palumbo, A., Storb, R., Ciccone, G., Boccadoro, M. (2007). A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. NEJM 356: 1110-1120 [Abstract] [Full Text]  
• Podar, K., Raab, M. S., Zhang, J., McMillin, D., Breitkreutz, I., Tai, Y.-T., Lin, B. K., Munshi, N., Hideshima, T., Chauhan, D., Anderson, K. C. (2007). Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 109: 1669-1677 [Abstract] [Full Text]  
• Sekimoto, E., Ozaki, S., Ohshima, T., Shibata, H., Hashimoto, T., Abe, M., Kimura, N., Hattori, K., Kawai, S., Kinoshita, Y., Yamada-Okabe, H., Tsuchiya, M., Matsumoto, T. (2007). A Single-Chain Fv Diabody against Human Leukocyte Antigen-A Molecules Specifically Induces Myeloma Cell Death in the Bone Marrow Environment. Cancer Res. 67: 1184-1192 [Abstract] [Full Text]  
• Grube, M., Moritz, S., Obermann, E. C., Rezvani, K., Mackensen, A., Andreesen, R., Holler, E. (2007). CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma. Clin. Cancer Res. 13: 1053-1060 [Abstract] [Full Text]  
• Atanackovic, D., Arfsten, J., Cao, Y., Gnjatic, S., Schnieders, F., Bartels, K., Schilling, G., Faltz, C., Wolschke, C., Dierlamm, J., Ritter, G., Eiermann, T., Hossfeld, D. K., Zander, A. R., Jungbluth, A. A., Old, L. J., Bokemeyer, C., Kroger, N. (2007). Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109: 1103-1112 [Abstract] [Full Text]  
• Zamagni, E., Nanni, C., Patriarca, F., Englaro, E., Castellucci, P., Geatti, O., Tosi, P., Tacchetti, P., Cangini, D., Perrone, G., Ceccolini, M., Brioli, A., Buttignol, S., Fanin, R., Salizzoni, E., Baccarani, M., Fanti, S., Cavo, M. (2007). A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. haematol 92: 50-55 [Abstract] [Full Text]  
• Dawson, M. A., Patil, S., Spencer, A. (2007). Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. haematol 92: 143-144 [Abstract] [Full Text]  
• Podar, K., Tonon, G., Sattler, M., Tai, Y.-T., LeGouill, S., Yasui, H., Ishitsuka, K., Kumar, S., Kumar, R., Pandite, L. N., Hideshima, T., Chauhan, D., Anderson, K. C. (2006). The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl. Acad. Sci. USA 103: 19478-19483 [Abstract] [Full Text]  
• Giuliani, N., Rizzoli, V., Roodman, G. D. (2006). Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108: 3992-3996 [Abstract] [Full Text]  
• Landgren, O., Zhang, Y., Zahm, S. H., Inskip, P., Zheng, T., Baris, D. (2006). Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women. Cancer Epidemiol. Biomarkers Prev. 15: 2342-2347 [Abstract] [Full Text]  
• Dalton, W., Anderson, K. C. (2006). Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma.. Clin. Cancer Res. 12: 6603-6610 [Abstract] [Full Text]  
• Yip, K. W., Mao, X., Au, P.Y. B., Hedley, D. W., Chow, S., Dalili, S., Mocanu, J. D., Bastianutto, C., Schimmer, A., Liu, F.-F. (2006). Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen.. Clin. Cancer Res. 12: 5557-5569 [Abstract] [Full Text]  
• Korbet, S. M., Schwartz, M. M. (2006). Multiple Myeloma. J. Am. Soc. Nephrol. 17: 2533-2545 [Full Text]  
• Yageman, L. A, Cronin, S. M, Peres, E., Abidi, M. H, Ibrahim, R. B (2006). Palifermin in a hematopoietic stem cell transplant patient with osteonecrosis of the jaw. J Oncol Pharm Pract 12: 119-121 [Abstract]  
• Carneiro, E., Vibhute, P., Montazem, A., Som, P.M. (2006). Bisphosphonate-associated mandibular osteonecrosis.. Am. J. Neuroradiol. 27: 1096-1097 [Abstract] [Full Text]  
• Dingli, D., Nowakowski, G. S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Rajkumar, S. V., Greipp, P. R., Litzow, M. R., Gastineau, D. A., Witzig, T. E., Gertz, M. A. (2006). Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood 107: 3384-3388 [Abstract] [Full Text]  
• Schonland, S. O., Lokhorst, H., Buzyn, A., Leblond, V., Hegenbart, U., Bandini, G., Campbell, A., Carreras, E., Ferrant, A., Grommisch, L., Jacobs, P., Kroger, N., La Nasa, G., Russell, N., Zachee, P., Goldschmidt, H., Iacobelli, S., Niederwieser, D., Gahrton, G., for the Chronic Leukemia Working Party (CLWP), Mye, (2006). Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 107: 2578-2584 [Abstract] [Full Text]  
• Cavo, M., Baccarani, M. (2006). The Changing Landscape of Myeloma Therapy. NEJM 354: 1076-1078 [Full Text]  
• Barlogie, B., Kyle, R. A., Anderson, K. C., Greipp, P. R., Lazarus, H. M., Hurd, D. D., McCoy, J., Dakhil, S. R., Lanier, K. S., Chapman, R. A., Cromer, J. N., Salmon, S. E., Durie, B., Crowley, J. C. (2006). Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321. JCO 24: 929-936 [Abstract] [Full Text]  
• Maier, S. K, Hammond, J. M (2006). Role of Lenalidomide in the Treatment of Multiple Myeloma and Myelodysplastic Syndrome. The Annals of Pharmacotherapy 40: 286-289 [Abstract] [Full Text]  
• Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., Greipp, P. R. (2006). Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. JCO 24: 431-436 [Abstract] [Full Text]  
• Orlowski, R. Z. (2006). Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. ASH Education Book 2006: 338-347 [Abstract] [Full Text]  
• Qian, J., Wang, S., Yang, J., Xie, J., Lin, P., Freeman, M. E. III, Yi, Q. (2005). Targeting Heat Shock Proteins for Immunotherapy in Multiple Myeloma: Generation of Myeloma-Specific CTLs Using Dendritic Cells Pulsed with Tumor-Derived gp96. Clin. Cancer Res. 11: 8808-8815 [Abstract] [Full Text]  
• Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., Lust, J. A., Russell, S. J., Kyle, R. A., Witzig, T. E., Gertz, M. A. (2005). Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106: 4050-4053 [Abstract] [Full Text]  
• David, E., Sun, S.-Y., Waller, E. K., Chen, J., Khuri, F. R., Lonial, S. (2005). The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 106: 4322-4329 [Abstract] [Full Text]  
• Clark, W. F., Stewart, A. K., Rock, G. A., Sternbach, M., Sutton, D. M., Barrett, B. J., Heidenheim, A. P., Garg, A. X., Churchill, D. N., the Canadian Apheresis Group, (2005). Plasma Exchange When Myeloma Presents as Acute Renal Failure: A Randomized, Controlled Trial. ANN INTERN MED 143: 777-784 [Abstract] [Full Text]  
• Blade, J., Rosinol, L., Sureda, A., Ribera, J. M., Diaz-Mediavilla, J., Garcia-Larana, J., Mateos, M. V., Palomera, L., Fernandez-Calvo, J., Marti, J. M., Giraldo, P., Carbonell, F., Callis, M., Trujillo, J., Gardella, S., Moro, M. J., Barez, A., Soler, A., Font, L., Fontanillas, M., Miguel, J. S., for Programa para el Estudio de la Terapeutica en, (2005). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106: 3755-3759 [Abstract] [Full Text]  
• Jalili, A., Ozaki, S., Hara, T., Shibata, H., Hashimoto, T., Abe, M., Nishioka, Y., Matsumoto, T. (2005). Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood 106: 3538-3545 [Abstract] [Full Text]  
• Reisfield, G. M., Paulian, G. D., Wilson, G. R. (2005). "Johnny can't read": Another cause " of failed analgesia. AM J HOSP PALLIAT CARE 22: 433-436  
• Giuliani, N., Colla, S., Morandi, F., Lazzaretti, M., Sala, R., Bonomini, S., Grano, M., Colucci, S., Svaldi, M., Rizzoli, V. (2005). Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106: 2472-2483 [Abstract] [Full Text]  
• Kumar, S., Rajkumar, S. V., Kyle, R. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Lust, J. A., Gertz, M. A., Greipp, P. R., Witzig, T. E. (2005). Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance. JCO 23: 5668-5674 [Abstract] [Full Text]  
• Yasui, H., Hideshima, T., Raje, N., Roccaro, A. M., Shiraishi, N., Kumar, S., Hamasaki, M., Ishitsuka, K., Tai, Y.-T., Podar, K., Catley, L., Mitsiades, C. S., Richardson, P. G., Albert, R., Brinkmann, V., Chauhan, D., Anderson, K. C. (2005). FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance. Cancer Res. 65: 7478-7484 [Abstract] [Full Text]  
• Girlanda, S., Fortis, C., Belloni, D., Ferrero, E., Ticozzi, P., Sciorati, C., Tresoldi, M., Vicari, A., Spies, T., Groh, V., Caligaris-Cappio, F., Ferrarini, M. (2005). MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated {gamma}{delta} Lymphocytes. Cancer Res. 65: 7502-7508 [Abstract] [Full Text]  
• Rajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J. III, Bradwell, A. R., Clark, R. J., Larson, D. R., Plevak, M. F., Dispenzieri, A., Katzmann, J. A. (2005). Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106: 812-817 [Abstract] [Full Text]  
• Yasui, H., Hideshima, T., Hamasaki, M., Roccaro, A. M., Shiraishi, N., Kumar, S., Tassone, P., Ishitsuka, K., Raje, N., Tai, Y.-T., Podar, K., Chauhan, D., Leoni, L. M., Kanekal, S., Elliott, G., Munshi, N. C., Anderson, K. C. (2005). SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 106: 706-712 [Abstract] [Full Text]  
• Rajkumar, S. V. (2005). Multiple myeloma: the death of VAD as initial therapy. Blood 106: 2-3 [Full Text]  
• Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., de Vivo, A., Testoni, N., Nicci, C., Terragna, C., Grafone, T., Perrone, G., Ceccolini, M., Tura, S., Baccarani, M., for the writing committee of the Bologna 2002 stud, (2005). Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106: 35-39 [Abstract] [Full Text]  
• Kienast, J., Berdel, W. E. (2005). Another dangerous traveler in myeloma blood?. Blood 105: 3009-3010 [Full Text]  
• Scheindlin, S. (2005). THE DUPLICITOUS NATURE OF INORGANIC ARSENIC. Mol. Interv. 5: 60-64 [Full Text]  
• Schaar, C. G., Kluin-Nelemans, H. C., te Marvelde, C., le Cessie, S., Breed, W. P., Fibbe, W. E., van Deijk, W. A., Fickers, M. M., Roozendaal, K. J., Wijermans, P. W., On behalf of the Dutch-Belgian Hemato-Oncology Coo, (2005). Interferon-{alpha} as maintenance therapy in patients with multiple myeloma. Ann Oncol 16: 634-639 [Abstract] [Full Text]  
• Altundag, K., Altundag, O., Gundeslioglu, O., Crawford, C. L., Schneider, H. G., Sentry, J., Kyle, R. A., Rajkumar, S. V. (2005). Multiple Myeloma. NEJM 352: 840-841 [Full Text]  
• Rajkumar, S. V. (2005). MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management. ASH Education Book 2005: 340-345 [Abstract] [Full Text]